Cargando…
Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response
Cancer will directly affect the lives of over one-third of the population. The DNA Damage Response (DDR) is an intricate system involving damage recognition, cell cycle regulation, DNA repair, and ultimately cell fate determination, playing a central role in cancer etiology and therapy. Two primary...
Autores principales: | Wilson, David M., Deacon, Ashley M., Duncton, Matthew A.J., Pellicena, Patricia, Georgiadis, Millie M., Yeh, Andrew P., Arvai, Andrew S., Moiani, Davide, Tainer, John A., Das, Debanu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666131/ https://www.ncbi.nlm.nih.gov/pubmed/33115610 http://dx.doi.org/10.1016/j.pbiomolbio.2020.10.005 |
Ejemplares similares
-
Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH)
por: Wilson, David M., et al.
Publicado: (2021) -
Mre11 ATLD17/18 mutation retains Tel1/ATM activity but blocks DNA double-strand break repair
por: Limbo, Oliver, et al.
Publicado: (2012) -
CaMKII inhibitors: from research tools to therapeutic agents
por: Pellicena, Patricia, et al.
Publicado: (2014) -
An effective human uracil-DNA glycosylase inhibitor targets the open pre-catalytic active site conformation
por: Nguyen, My T., et al.
Publicado: (2021) -
Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
por: Brosey, Chris A., et al.
Publicado: (2021)